🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

Debiopharm International clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our USA and UK registers with Debiopharm International as lead sponsor. Synced 26 Sep 2026
5Current trials
4Recruiting now
0Drugs in these trials
2Trial registers
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

Debiopharm International is the lead sponsor of 5 current clinical trials in our USA and UK registers. 4 are recruiting patients now. The most common phase is Phase 3. The most-studied condition is Advanced Solid Tumor.

ClinicalTrials.gov trials by status

  • Recruiting480%
  • Active, closed120%

Trials by phase

  • Phase 3240%
  • Phase 1/2240%
  • Phase 1120%
01

Clinical trials sponsored by Debiopharm International

5 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
Study of Lunresertib Alone or in Combination With RP-3500 or Debio 0123 in Patients With Advanced Solid Tumors
NCT04855656 · Advanced Solid Tumor
Phase 1 Recruiting 2021-04 UK, USA
A Study to Assess the Efficacy and Safety of Debio 4126 in Participants With Acromegaly Previously Treated With Somatostatin Analogs
NCT06930625 · ClinicalTrials.gov ↗ · Acromegaly
Phase 3 Recruiting 2025-11 UK, USA
A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma
NCT05765812 · ClinicalTrials.gov ↗ · Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype, Astrocytoma, Grade III
Phase 1/2 Recruiting 2023-05 USA
A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)
NCT06969430 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia
Phase 1/2 Recruiting 2025-05 USA
A Study to Assess the Efficacy, Safety, and Pharmacokinetics of Debio 4326 in Pediatric Participants With Central Precocious Puberty (LIBELULA™ Clinical Trial)
NCT06129539 · ClinicalTrials.gov ↗ · Central Precocious Puberty
Phase 3 Active, closed 2024-07 USA

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Conditions in Debiopharm International trials

6 conditions
Advanced Solid Tumor1Acromegaly1Central Precocious Puberty1Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype1Astrocytoma, Grade III1Acute Myeloid Leukemia1
03

By trial register

RegisterTrialsRecruiting
Clinical trials in USA54
Clinical trials in UK22

A trial with sites in more than one country appears in each of those registers.

04

Other sponsors in Advanced Solid Tumor

SponsorTrials
BeOne Medicines11
Daiichi Sankyo7
TORL Biotherapeutics5
OncoC45
LaNova Medicines5
MediLink Therapeutics (Suzhou)4
Suzhou Zelgen Biopharmaceuticals4
BioNTech3
EMD Serono Research & Development Institute3
Hansoh BioMedical R&D Company3

Sponsors with the most current trials registered for this condition.

05

Questions about Debiopharm International trials

How many clinical trials does Debiopharm International sponsor?

Debiopharm International is the lead sponsor of 5 current trials on ClinicalTrials.gov in our USA and UK registers, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Debiopharm International trials recruiting?

Yes. 4 of its 5 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.